Trans Cutaneous Electrical Acupoint Stimulation Versus TENS On Blood Pressure In Primary Hypertension Patients
1 other identifier
interventional
60
1 country
1
Brief Summary
To compare between the effects of transcutaneous electrical acupoint stimulation and TENS on blood pressure and quality of life in patients with primary hypertension BACKGROUND: The current American College of Cardiology and the American Heart Association (ACC/AHA) 2017 guidelines define hypertension as systolic BP (SBP) of ≥130 mmHg or diastolic BP (DBP) of ≥80 mmHg. In adults, an increase of 20 mmHg in SBP or 10 mmHg in DBP is associated with more than a two-fold increase in mortality owing to stroke and other cardiovascular diseases. Hypertension accounts for 13% of premature deaths worldwide and is the third leading cause of disability-adjusted life years (Shah et al., 2022). Transcutaneous electrical nerve stimulation of the Neiguan (P6) point with acupressure is possibly affecting the blood pressure by protecting the myocardial tissues and influencing the nervous system through regulating the autonomic nervous system function and reduction in sympathetic activity. (Hassanein et al., 2021). HYPOTHESES There will be no a significant difference between the effects of transcutaneous electrical acupoint stimulation and TENS on blood pressure and quality of life in patients with primary hypertension RESEARCH QUESTION: Is there a significant difference between the effects of transcutaneous electrical acupoint stimulation and TENS on blood pressure and quality of life in patients with primary hypertension? Evaluating equipment, pre-post intervension outcomes:
- 1.BP by Digital Sphygmomanometer
- 2.quality of life by The SF-12 health status questionnaire
- 3.nitric oxide level in blood by nitric Oxide analysis.
- 4.sleep quality. by Pittsburgh Sleep Quality Index (PSQI)
- 5.exercise capacity and endurance by Thirty-Second Sit-To-Stand Test (30 STST)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable hypertension
Started May 2024
Shorter than P25 for not_applicable hypertension
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 2, 2024
CompletedStudy Start
First participant enrolled
May 5, 2024
CompletedFirst Posted
Study publicly available on registry
May 6, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 5, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 10, 2024
CompletedMay 7, 2024
May 1, 2024
3 months
May 2, 2024
May 5, 2024
Conditions
Outcome Measures
Primary Outcomes (3)
Blood Pressure by using a digital sphygmomanometer
Blood pressure was recorded by using a digital sphygmomanometer
six weeks
quality of life by Short Form twelve health status questionnaire
by Short Form twelve health status questionnaire Health-Related Quality of Life survey consisting of twelve questions that measure eight health domains to assess physical and mental health.The score ranges from 0 to 100, with a higher score indicating better physical and mental health functioning.
six weeks
Nitric oxide by nitric oxide sample analysis
by nitric oxide sample analysis
six weeks
Secondary Outcomes (2)
exercise capacity and endurance measured by Thirty-Second Sit-To-Stand Test (30 STST)
six weeks
sleep quality
six weeks
Study Arms (3)
Transcutaneous electrical acupoint stimulation (Group A):
EXPERIMENTALTranscutaneous electrical acupoint stimulation :It will be performed by using the TENS device on acupoint (TEAS) as the following: The patients will be placed in a relaxed comfortable sitting position with their back well supported. for 40 min three times weekly for a total of 6 weeks.The adhesive electrodes of the TENS device will be placed on the selected acupoint bilaterally Nei-Guan (PC6), Taichong (LR3), and Sanyinjiao (SP6)
Transcutaneous electrical nerve stimulation(Group b):
EXPERIMENTALTENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 min three times weekly for a total of 6 weeks.
Control
NO INTERVENTIONRoutine medical treatment: (Group c): receive only routine medical treatment (antihypertensive medication, instructions and education to control blood pressure) * Nutrition Eat a diet that is high in fiber and potassium, and low in salt (sodium), added sugar, and fat. * Lifestyle Do not use any products that contain nicotine or tobacco, such as cigarettes, and chewing tobacco. * Identify your sources of stress and find ways to manage stress. This may include deep breathing or making time for fun activities. * Do not drink alcohol
Interventions
It will be performed by using the TENS device on acupoint (TEAS) as the following: The patients will be placed in a relaxed comfortable sitting position with their back well supported. for 40 min three times weekly for a total of 6 weeks.The adhesive electrodes of the TENS device will be placed on the selected acupoint bilaterally Nei-Guan (PC6), Taichong (LR3), and Sanyinjiao (SP6)
TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 min three times weekly for a total of 6 weeks.
Eligibility Criteria
You may qualify if:
- \) Sixty patients from both sexes diagnosed with essential HT at least 6 months ago.
- \) Their age will be ranged from 50 to 60 years old. 3) Their blood pressure will be ranged from (SBP is 140 -159 mmHg and/or DBP is 90-99 mmHg).
- \) Their body mass index (BMI) ranged from will be ranged from 24.9 to 29.9 kg/m2.
- \) All patients are medically stable and receive the same medical treatment 6) All patient nonsmoker or quitted smoking for at least 4-5 years 7) All patients will be similar in terms of status of functional activity, status of eating a salt-free diet and the presence of any chronic disease except HT
You may not qualify if:
- \) Secondary hypertension 2) Patients with cardiac problems e.g. atrial fibrillation, left bundle-branch block, heart failure, recent myocardial infarction, coronary artery disease, or participation in cardiac rehabilitation following bypass surgery.
- \) Patients with history, symptoms of, and/or laboratory reports suggestive of renal, neurologic, or hepatic complications.
- \) Use of a cardiac pacemaker 5) Any metal implants at site of application of TENS 6) Dermatological abnormalities at the site of the application of TENS 7) Obesity with body mass index (BMI) \> 30 kg/m2 8) Smoker, diabetes. 9) Soft tissue, nerve, and vascular diseases of upper or lower extremities which hinder the application of TEAS.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Faculty of physical therapy- Cairo Uni.
Giza, 12611, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Assistant Lecturer
Study Record Dates
First Submitted
May 2, 2024
First Posted
May 6, 2024
Study Start
May 5, 2024
Primary Completion
August 5, 2024
Study Completion
August 10, 2024
Last Updated
May 7, 2024
Record last verified: 2024-05
Data Sharing
- IPD Sharing
- Will not share